Inovio Pharmaceuticals (INO) Exchange Rate Effect (2010 - 2024)
Inovio Pharmaceuticals (INO) posted Exchange Rate Effect of $32403.0 for Q1 2024, up 6608.7% sequentially from $483.0 in Q4 2023, and up 1789.42% YoY from $1715.0 in Q2 2023.
Inovio Pharmaceuticals (INO) Exchange Rate Effect (2010 - 2024) Analysis & Trends
Inovio Pharmaceuticals has reported Exchange Rate Effect for 10 years, with the latest figure at $32403.0 in Q1 2024.
- Quarterly Exchange Rate Effect rose 1789.42% year-over-year to $32403.0 in Q1 2024, while the trailing twelve-month figure through Dec 2024 was $32403.0 (up 926.61% YoY) and the FY2024 annual result came in at $32403.0, up 926.61% from the prior year.
- Exchange Rate Effect grew to $32403.0 in Q1 2024 per INO's latest filing, from $483.0 in the prior quarter.
- Over five years, Exchange Rate Effect peaked at $32403.0 in Q1 2024 and troughed at -$16563.0 in Q3 2022.
- A 5-year average of -$0.13 and a median of -$1918.0 in 2023 frame the typical range for Exchange Rate Effect.
- The sharpest annual moves came in 2022 and 2024: Exchange Rate Effect sank 696.65% in 2022, then jumped 1789.42% in 2024.
- Over 5 years, Exchange Rate Effect stood at $21021.0 in 2020, then slumped by 134.83% to -$7321.0 in 2021, then surged by 268.65% to $12347.0 in 2022, then tumbled by 96.09% to $483.0 in 2023, then jumped by 6608.7% to $32403.0 in 2024.
- According to Business Quant data, Exchange Rate Effect over the past three periods registered $32403.0, $483.0, and -$2109.0 for Q1 2024, Q4 2023, and Q3 2023 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Exchange Rate Effect (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.35 Bn | 131.50 Bn | 2.84 Bn | -3.70 Mn |
| 2 | Regeneron Pharmaceuticals | 86.12 Bn | 78.12 Bn | 3.93 Bn | -300,000.00 |
| 3 | Argenx Se | 65.22 Bn | 60.03 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.98 Bn | 53.84 Bn | 52.00 Mn | -2.00 Mn |
| 5 | BeOne Medicines | 42.08 Bn | 36.99 Bn | 1.53 Bn | 19.84 Mn |
| 6 | Alnylam Pharmaceuticals | 31.61 Bn | 28.30 Bn | 992.69 Mn | -2.45 Mn |
| 7 | BioNTech SE | 27.98 Bn | 9.59 Bn | 668.28 Mn | 1.63 Mn |
| 8 | Insmed | 27.46 Bn | 26.30 Bn | 358.27 Mn | -287,000.00 |
| 9 | Royalty Pharma | 27.30 Bn | 26.47 Bn | - | - |
| 10 | Inovio Pharmaceuticals | 96.39 Mn | 96.39 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2024 | 32,403.00 |
| Mar 31, 2024 | 32,403.00 |
| Dec 31, 2023 | 483.00 |
| Dec 31, 2023 | 483.00 |
| Sep 30, 2023 | -2,109.00 |
| Sep 30, 2023 | -2,109.00 |
| Jun 30, 2023 | -376.00 |
| Jun 30, 2023 | -376.00 |
| Mar 31, 2023 | -1,918.00 |
| Mar 31, 2023 | -1,918.00 |
| Dec 31, 2022 | 12,347.00 |
| Dec 31, 2022 | 12,347.00 |
| Sep 30, 2022 | -16,563.00 |
| Sep 30, 2022 | -16,563.00 |
| Jun 30, 2022 | -14,785.00 |
| Jun 30, 2022 | -14,785.00 |
| Mar 31, 2022 | -6,555.00 |
| Mar 31, 2022 | -6,555.00 |
| Dec 31, 2021 | -7,321.00 |
| Dec 31, 2021 | -7,321.00 |